The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results

Lauren S. Singer, Alexander Z. Feldman, Robin A. Buerki, Craig M. Horbinski, Rimas V. Lukas, Roger Stupp*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

In 2016, the World Health Organization (WHO) released the most recent update to the classification of central nervous system tumors. This update has led to the reshaping of tumor identification and subsequently changed current understanding of treatment options for patients. Moreover, the restructuring of the classification of central nervous system tumors to include molecular markers has led to the need to re-evaluate how to interpret pivotal trials. These trials originally enrolled patients purely based upon histologic diagnoses without the use of adjunctive, and frequently diagnostic molecular testing. With this new paradigm also comes the need to assess how one should incorporate molecular markers into current trials as well as shape future trials. First, we will discuss updates on the molecular classification of glioblastoma (GBM) (and its histologic mimics). This will be followed by a review of key pivotal trials which have defined our standard of care for glioblastoma within the context of molecular classification of their study populations. This will be followed by preliminary results of ongoing phase 3 cooperative group trials for high-grade gliomas that were initiated prior to routine molecular classification of tumors and how one could interpret these results in light of advances in molecular classification. Finally, we will end with suggestions for future clinical trial design with a focus on enrollment based upon molecular diagnostics.

Original languageEnglish (US)
Article number33
JournalChinese clinical oncology
Volume10
Issue number4
DOIs
StatePublished - Aug 2021

Keywords

  • Astrocytoma
  • Clinical trial
  • Glioblastoma (GBM)
  • IDH
  • Neuropathology

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results'. Together they form a unique fingerprint.

Cite this